C-peptide vs DPDPE
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and DPDPE ([D-Pen2, D-Pen5]-enkephalin) — benefits, dosing, side effects, research data, and where to buy.
| Property | C-peptide | DPDPE |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | Connecting peptide (C-peptide) | [D-Pen2, D-Pen5]-enkephalin |
| Molecular Weight | 3020.3 Da | 645.79 Da |
| Half-Life | ~20-30 min | 15-60 minutes in plasma |
| Amino Acids | 31 | 5 |
| Typical Dose | no approved analgesic dose|research-only | 0.01-1 ug per animal |
| Route | IV|subQ | Intrathecal / intracerebroventricular |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 800 |
| Research Status | Pre-clinical | Pre-clinical |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
DPDPE Benefits
- ✓delta-opioid selectivity
- ✓improved conformational stability
- ✓analgesic receptor mapping
- ✓useful in chronic pain models
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
DPDPE Dosing
Intrathecal 0.01-1 ug per animal|Intracerebroventricular 0.01-0.5 ug per animal|In vitro 0.1-20 nM
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
DPDPE Side Effects
- ⚠sedation
- ⚠nausea-like opioid effects
- ⚠tolerance with repeated dosing
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
DPDPE
DPDPE is widely cited in opioid pharmacology because it helped establish the functional role of delta-opioid receptors in pain control. Its constrained structure is also used to explore how peptide cyclization changes potency, stability, and tissue selectivity.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.